Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 12/2019

01.12.2019 | GI Oncology (R Bresalier, Section Editor)

Gastrointestinal Motility Issues in Cancer Patients

verfasst von: Mehnaz A. Shafi

Erschienen in: Current Gastroenterology Reports | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This paper seeks to highlight GI motility disorders that are frequently present in patients with a malignancy. GI dysmotility can occur due to the cancer itself or as a consequence of medical and surgical treatments. Often, symptoms are nonspecific and the diagnosis requires a high index of suspicion. The goal of the paper is to review the common motility problems seen in patients with cancer, their clinical manifestations, and options for management.

Recent Findings

Studies show that newer endoscopy techniques such as endoscopic mucosal dissection can cause esophageal dysmotility. Opioid-induced constipation is frequently encountered in patients with cancer.

Summary

Motility disorders in cancer patient can lead to clinical morbidity, poor quality of life, and malnutrition. Newer diagnostic tests and medical and surgical treatments may be helpful in improving the diagnosis and management of these disorders.
Literatur
1.
2.
Sanders KM, Koh SD, Ro S, Ward SM. Regulation of gastrointestinal motility--insights from smooth muscle biology. Nat Rev Gastroenterol Hepatol. 2012;9(11):633–45.PubMedPubMedCentralCrossRef
3.
Hejazi RA, Zhang D, McCallum RW. Gastroparesis, pseudoachalasia and impaired intestinal motility as paraneoplastic manifestations of small cell lung cancer. Am J Med Sci. 2009;338(1):69–71.PubMedCrossRef
4.
•• DiBaise JK. Paraneoplastic gastrointestinal dysmotility: when to consider and how to diagnose. Gastroenterol Clin North Am. 2011;40(4):777–86. This paper gives a thorough description of the major paraneoplastic disorders that can cause GI dysmotility. PubMedCrossRef
5.
Grover M, Camilleri M. Treatment with methylnaltrexone and IVIG for paraneoplastic gastrointestinal dysmotility. Gastroenterol Hepatol (N Y). 2013;9(1):51–3.
6.
Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22(9):e256–61.PubMedCrossRef
7.
Katzka DA, Farrugia G, Arora AS. Achalasia secondary to neoplasia: a disease with a changing differential diagnosis. Dis Esophagus. 2012;25(4):331–6.PubMedCrossRef
8.
Ponds FA, van Raath MI, Mohamed SMM, Smout A, Bredenoord AJ. Diagnostic features of malignancy-associated pseudoachalasia. Aliment Pharmacol Ther. 2017;45(11):1449–58.PubMedCrossRef
9.
Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238–49 quiz 50.PubMedCrossRef
10.
• Hirano I, Pandolfino JE, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15(3):325–34. This review gives a comprehensive overview of the use and indications of EndoFLIP to evaluate esophageal dysmotility. PubMedPubMedCentralCrossRef
11.
Ahuja NK, Agnihotri A, Lynch KL, Hoo-Fatt D, Onyimba F, McKnight M, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Dis Esophagus. 2017;30(8):1–8.PubMedCrossRef
12.
13.
Bu BG, Linghu EQ, Li HK, Wang XX, Guo RB, Peng LH. Influence of endoscopic submucosal dissection on esophageal motility. World J Gastroenterol. 2013;19(29):4781–5.PubMedPubMedCentralCrossRef
14.
Takahashi K, Sato Y, Takeuchi M, Sato H, Nakajima N, Ikarashi S, et al. Changes in esophageal motility after endoscopic submucosal dissection for superficial esophageal cancer: a high-resolution manometry study. Dis Esophagus. 2017;30(11):1–8.PubMedCrossRef
15.
Kuribayashi Y, Iizuka T, Nomura K, Furuhata T, Yamashita S, Matsui A, et al. Esophageal motility after extensive circumferential endoscopic submucosal dissection for superficial esophageal cancer. Digestion. 2018;98(3):153–60.PubMedCrossRef
16.
Takahashi K, Takeuchi M, Sato Y, Sato H, Mizuno K, Hashimoto S, et al. Evaluation of esophageal motility after endoscopic submucosal dissection for superficial esophageal cancer. Eur J Gastroenterol Hepatol. 2015;27(10):1187–92.PubMedCrossRef
17.
Huddy JR, Macharg FM, Lawn AM, Preston SR. Exocrine pancreatic insufficiency following esophagectomy. Dis Esophagus. 2013;26(6):594–7.PubMedCrossRef
18.
Mehran R, Rice D, El-Zein R, Huang JL, Vaporciyan A, Goodyear A, et al. Minimally invasive esophagectomy versus open esophagectomy, a symptom assessment study. Dis Esophagus. 2011;24(3):147–52.PubMedCrossRef
19.
Smith DS, Williams CS, Ferris CD. Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. Gastroenterol Clin N Am. 2003;32(2):619–58.CrossRef
20.
Antonoff MB, Puri V, Meyers BF, Baumgartner K, Bell JM, Broderick S, et al. Comparison of pyloric intervention strategies at the time of esophagectomy: is more better? Ann Thorac Surg. 2014;97(6):1950–7 discussion 657–8.PubMedPubMedCentralCrossRef
21.
Fuchs HF, Broderick RC, Harnsberger CR, Divo FA, Coker AM, Jacobsen GR, et al. Intraoperative endoscopic Botox injection during total esophagectomy prevents the need for pyloromyotomy or dilatation. J Laparoendosc Adv Surg Tech A. 2016;26(6):433–8.PubMedCrossRef
22.
•• Zhang L, Hou SC, Miao JB, Lee H. Risk factors for delayed gastric emptying in patients undergoing esophagectomy without pyloric drainage. J Surg Res. 2017;213:46–50. This study highlights the risk factors that may predispose to delayed gastric emptying in patients undergoing esophagectomy. PubMedCrossRef
23.
Zhang T, Maclean J, Szczesniak M, Bertrand PP, Quon H, Tsang RK, et al. Esophageal dysmotility in patients following total laryngectomy. Otolaryngol Head Neck Surg. 2018;158(2):323–30.PubMedCrossRef
24.
Szczesniak MM, Maclean J, Zhang T, Graham PH, Cook IJ. Persistent dysphagia after head and neck radiotherapy: a common and under-reported complication with significant effect on non-cancer-related mortality. Clin Oncol (R Coll Radiol). 2014;26(11):697–703.CrossRef
25.
Wu PI, Szczesniak MM, Maclean J, Choo L, Quon H, Graham PH, et al. Clinical utility of a functional lumen imaging probe in management of dysphagia following head and neck cancer therapies. Endoscopy. 2017;49(9):848–54.PubMedCrossRef
26.
Kinami S, Takahashi M, Urushihara T, Ikeda M, Yoshida M, Uenosono Y, et al. Background factors influencing postgastrectomy syndromes after various types of gastrectomy. World J Clin Cases. 2018;6(16):1111–20.PubMedPubMedCentralCrossRef
27.
Tanizawa Y, Tanabe K, Kawahira H, Fujita J, Takiguchi N, Takahashi M, et al. Specific features of dumping syndrome after various types of gastrectomy as assessed by a newly developed integrated questionnaire, the PGSAS-45. Dig Surg. 2016;33(2):94–103.PubMedCrossRef
28.
van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev. 2017;18(1):68–85.PubMedCrossRef
29.
Valderas JP, Ahuad J, Rubio L, Escalona M, Pollak F, Maiz A. Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg. 2012;22(4):582–6.PubMedCrossRef
30.
Chiappetta S, Stier C. A case report: liraglutide as a novel treatment option in late dumping syndrome. Medicine (Baltimore). 2017;96(12):e6348.CrossRef
31.
Shafi MA, Pasricha PJ. Post-surgical and obstructive gastroparesis. Curr Gastroenterol Rep. 2007;9(4):280–5.PubMedCrossRef
32.
Shah H, Wendorf G, Ahmed S, McElmurray L, Lahr C, Hughes M, et al. Treating an oft-unrecognized and troublesome entity: using gastric electrical stimulation to reduce symptoms of malignancy-associated gastroparesis. Support Care Cancer. 2017;25(1):27–31.PubMedCrossRef
33.
• Watanabe K, Hikichi T, Sato M, Nakamura J, Obara K, Ohira H. Change in gastric emptying eight weeks after endoscopic submucosal dissection in patients with early gastric cancer. Endosc Int Open. 2016;4(5):E597–602. This study highlights motility disturbances that can result after ESD treatment for gastric cancer. PubMedPubMedCentralCrossRef
34.
Park YS, Shin DJ, Son SY, Kim KH, Park DJ, Ahn SH, et al. Roux stasis syndrome and gastric food stasis after laparoscopic distal gastrectomy with uncut Roux-en-Y reconstruction in gastric cancer patients: a propensity score matching analysis. World J Surg. 2018;42(12):4022–32.PubMedCrossRef
35.
Herbella FA, Silva LC, Vicentine FP, Patti MG. Roux-en-Y limb motility after total gastrectomy. J Gastrointest Surg. 2014;18(5):906–10.PubMedCrossRef
36.
Sorhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer. 2005;48(1):137–40.PubMedCrossRef
37.
Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.PubMedCrossRef
38.
Deng L, Liu Y, Zhang D, Li Y, Xu L. Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer. Mol Clin Oncol. 2016;4(5):883–7.PubMedPubMedCentralCrossRef
39.
• Heneghan HM, Zaborowski A, Fanning M, McHugh A, Doyle S, Moore J, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg. 2015;262(5):803–7; discussion 7–8. This study evaluates the nutritional challenges in patients after surgery for esophageal and gastric cancer. PubMedCrossRef
40.
Liang S, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol. 2016;27(3):227–32.PubMedCrossRef
41.
Kumagai T, Rahman F, Smith AM. The microbiome and radiation induced-bowel injury: evidence for potential mechanistic role in disease pathogenesis. Nutrients. 2018;10(10).PubMedCentralCrossRef
42.
Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24(3–4):228–42.PubMedCrossRef
43.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016.
44.
•• Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386–95. This is a comprehensive overview of the prevalence and management of opioid-induced constipation. PubMedPubMedCentralCrossRef
45.
Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–96.PubMedCrossRef
46.
Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–66.PubMedCrossRef
47.
Ratuapli SK, Crowell MD, DiBaise JK, Vela MF, Ramirez FC, Burdick GE, et al. Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110(7):979–84.PubMedCrossRef
48.
McQuade RM, Stojanovska V, Stavely R, Timpani C, Petersen AC, Abalo R, et al. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol. 2018;175(4):656–77.PubMedPubMedCentralCrossRef
49.
McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.PubMedCrossRef
50.
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414.PubMedPubMedCentralCrossRef
Metadaten
Titel
Gastrointestinal Motility Issues in Cancer Patients
verfasst von
Mehnaz A. Shafi
Publikationsdatum
01.12.2019
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 12/2019
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-019-0738-x

Weitere Artikel der Ausgabe 12/2019

Current Gastroenterology Reports 12/2019 Zur Ausgabe

Gastroenterology in Geriatric Patients (S Chokhavatia, Section Editor)

Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem

Small Intestine (D Sachar, Section Editor)

Principles and Practice of Oral Rehydration

Stomach and Duodenum (J Pisegna and J Benhammou, Section Editors)

EUS-Guided Portal Venous Sampling of Circulating Tumor Cells

Nutrition and Obesity (S McClave, Section Editor)

Controversy in Nutrition Recommendations for Short Bowel Syndrome: How Type of SBS Impacts Response

Pediatric Gastroenterology (S Orenstein and S Khan, Section Editors)

Pediatric Intestinal Pseudo-obstruction in the Era of Genetic Sequencing

Esophagus (J Clarke and N Ahuja, Section Editors)

Tips for the Budding Esophagologist

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise